Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
WHO introduceert de ‘Toolkit for research and development of paediatric antiretroviral drugs and formulations’
sep 2019 | HIV